BEDMINSTER, N.J.--(BUSINESS WIRE)--Somnus Therapeutics, Inc. (“Somnus”), a private specialty pharmaceutical company developing a controlled-release drug as a sleep-maintenance therapeutic to treat insomnia, today announced the initial four members of its board of directors:
